Fyyaz S, Rasoul H, Miles C, Olabintan O, David S, Plein S, Alfakih K
Department of Cardiology, Lewisham and Greenwich NHS Trust, Lewisham and Greenwich NHS Trust, London, UK.
Cardiology Clinical Academic Group, St George's University Hospital, London.
JRSM Cardiovasc Dis. 2021 Jul 18;10:20480040211032789. doi: 10.1177/20480040211032789. eCollection 2021 Jan-Dec.
The European Society of Cardiology (ESC) published an updated stable chest pain guideline in 2019, recommending the use of an updated pre-test probability (PTP) risk score (RS) to assess the likelihood of coronary artery disease (CAD). We sought to compare the 2019 and 2013 PTPRS in a contemporary cohort of patients.
612 patients who were investigated with computed tomography coronary angiography (CTCA) for stable chest pain were included in a retrospective analysis.
There were 255 patients with 2019 PTPRS 15-50% with a 9% yield of severe CAD on CTCA, compared with 402 patients and a 4% yield using the 2013 PTPRS (p = 0.01). 355 patients had a 2019 PTPRS of <15%, with 3% found to have severe CAD, compared with 67 patients and none with severe CAD using the 2013 PTPRS (p = 0.14). 336 of patients with 2019 PTPRS of <15% had a calcium score as part of the CTCA. 223 of these had a zero calcium score and only one had severe CAD. In comparison, 113 patients had a positive calcium score, and 10 (9%) had severe CAD (p < 0.001).
The ESC 2019 PTPRS classifies more patients as at lower risk of CAD and hence reduces the risk overestimation associated with the 2013 PTPRS. However, in patients with a 2019 PTPRS of <15%, who would not be investigated, the use of the calcium score detected the majority of patients with significant CAD, who may benefit from secondary prevention and an associated mortality benefit as per the SCOT-Heart trial.
欧洲心脏病学会(ESC)于2019年发布了一份更新的稳定型胸痛指南,建议使用更新后的预检概率(PTP)风险评分(RS)来评估冠状动脉疾病(CAD)的可能性。我们试图在当代患者队列中比较2019年和2013年的PTPRS。
对612例因稳定型胸痛接受计算机断层扫描冠状动脉造影(CTCA)检查的患者进行回顾性分析。
255例患者的2019年PTPRS为15%-50%,CTCA检查中严重CAD的检出率为9%,而使用2013年PTPRS的402例患者的检出率为4%(p = 0.01)。355例患者的2019年PTPRS<15%,其中3%被发现患有严重CAD,而使用2013年PTPRS的67例患者中无一例患有严重CAD(p = 0.14)。336例2019年PTPRS<15%的患者将钙评分作为CTCA的一部分。其中223例钙评分为零,只有1例患有严重CAD。相比之下,113例患者钙评分呈阳性,10例(9%)患有严重CAD(p<0.001)。
ESC 2019年PTPRS将更多患者归类为CAD低风险,从而降低了与2013年PTPRS相关的风险高估。然而,对于2019年PTPRS<15%且不会接受检查的患者,使用钙评分可检测出大多数患有显著CAD的患者,根据SCOT-Heart试验,这些患者可能从二级预防中获益并降低相关死亡率。